$599

Tandem, Amarin, and Intercept Q2 ’22 Earnings Updates; Anthem to Cover Eversense E3 Implantable CGM

A series of cardiometabolic-related news items have been observed: Tandem (press release), Amarin (press release; slides), and Intercept (press release; slides) hosted their respective earnings calls; and Senseonics announced Anthem is now covering implantable CGMs, including Senseonics’s Eversense E3 CGM. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here